Search Results 651-660 of 18512 for Relapse

  1. AKT Inhibitor MK2206, Combined with Bendamustine Hydrochloride, and Rituximab for Treating Patients who have Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma - Mayo Clinic

    AKT Inhibitor MK2206, Combined with Bendamustine Hydrochloride, and Rituximab for Treating Patients who have Relapsed Chronic Lymphocytic Leukemia or Small ...

  2. Medical Research & Education - Mayo Clinic News Network

    Study shows drug reduces risk of relapse with neuromyelitis optica featured image. Featured News. Study shows drug reduces risk of relapse with neuromyelitis ...

  3. Clinical trials - Oncology (Medical)

    This trial may help doctors find out what effects, good and/or bad, regimen UH-3 has on patients with newly diagnosed DAWT and standard risk relapsed FHWT ( ...

  4. Medical Research & Education - Mayo Clinic News Network

    Root Cause of Multiple Myeloma Relapse Revealed. Dana Sparks. September 18, 2013. Cancer. Mayo Clinic Receives $8.8 Million Federal Grant for Metabolomics ...

  5. Clinical trials - Oncology (Medical)

    This trial may help doctors find out what effects, good and/or bad, regimen UH-3 has on patients with newly diagnosed DAWT and standard risk relapsed FHWT ( ...

  6. Utkarsh Tripathi: Targeting Senescent Cells to Treat Aging and Cancer - Student Research - Mayo Clinic College of Medicine & Science

    ... relapse. These findings highlight the importance of tailoring senolytic treatments based on the unique characteristics of senescent cells, and have broad ...

  7. The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study - Mayo Clinic

    - Any first or greater B-ALL medullary relapse involving KMT2Ar; - Any first or greater T-ALL medullary relapse with or without KMT2Ar; - Patient has ...

  8. Medical Research & Education - Mayo Clinic News Network

    Mayo Clinic researchers link CAR-T cell aging to cancer relapse featured image. Featured News. Mayo Clinic researchers link CAR-T cell aging to cancer relapse.

  9. Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants with Relapsed or Refractory Multiple Myeloma - Mayo Clinic

    Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants with Relapsed or Refractory Multiple Myeloma ... relapsed or refractory ...

  10. Clinical trials - Oncology (Medical)

    ... relapsed acute leukemia (AML or ALL) for future biological studies. By accruing samples both at initial diagnosis and at relapse, we will be able to ...